Prediction of pathologic complete response to neoadjuvant chemoradiation in locally advanced rectal cancer. 2024

Xiaoling Zhong, and Guohua Zeng, and Lixiang Zhang, and Shuyuan You, and Yuxiang Fu, and Wan He, and Guixiang Liao
Department of Radiology, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, Guangdong, China.

To investigate the predictive factors of pathologic complete response (pCR) in locally advanced rectal cancer (LARC) patients who had been treated with neoadjuvant chemoradiation (nCRT). For this retrospective study, 53 LARC patients (37 males and 16 females; age range 25 to 79 years) were selected. Clinical characteristics, baseline mrTNM staging, MR gross tumor volumes (GTV), and pCR were evaluated. The diagnostic accuracy of GTV for predicting pCR was calculated. Among 53 LARC patients, 15 patients achieved pCR (28.3%), while 38 patients achieved non-pCR. Only three (5.7%) out of 53 patients did not downstage after nCRT. GTV and tumor differentiation were the significant prognostic parameters for predicting pCR. A tumor volume threshold of 21.1 cm3 was determined as a predictor for pCR, with a sensitivity of 84% and specificity of 47%. In addition, GTV was associated with mrN stage, circumferential resection margin (CRM) status, extramural vascular invasion (EMVI) status, and pretreatment serum CEA level. Tumor volume and tumor differentiation have significant predictive values in preoperative assessment of pCR among LARC patients. These findings aid clinicians to discriminate those patients who may likely benefit from preoperative regimens and to make optimal treatment plans.

UI MeSH Term Description Entries

Related Publications

Xiaoling Zhong, and Guohua Zeng, and Lixiang Zhang, and Shuyuan You, and Yuxiang Fu, and Wan He, and Guixiang Liao
October 2011, The American surgeon,
Xiaoling Zhong, and Guohua Zeng, and Lixiang Zhang, and Shuyuan You, and Yuxiang Fu, and Wan He, and Guixiang Liao
September 2021, American journal of clinical oncology,
Xiaoling Zhong, and Guohua Zeng, and Lixiang Zhang, and Shuyuan You, and Yuxiang Fu, and Wan He, and Guixiang Liao
January 2016, The British journal of radiology,
Xiaoling Zhong, and Guohua Zeng, and Lixiang Zhang, and Shuyuan You, and Yuxiang Fu, and Wan He, and Guixiang Liao
December 2021, The Israel Medical Association journal : IMAJ,
Xiaoling Zhong, and Guohua Zeng, and Lixiang Zhang, and Shuyuan You, and Yuxiang Fu, and Wan He, and Guixiang Liao
January 2021, Cancer management and research,
Xiaoling Zhong, and Guohua Zeng, and Lixiang Zhang, and Shuyuan You, and Yuxiang Fu, and Wan He, and Guixiang Liao
May 2023, Bioengineering (Basel, Switzerland),
Xiaoling Zhong, and Guohua Zeng, and Lixiang Zhang, and Shuyuan You, and Yuxiang Fu, and Wan He, and Guixiang Liao
September 2023, Clinical and translational radiation oncology,
Xiaoling Zhong, and Guohua Zeng, and Lixiang Zhang, and Shuyuan You, and Yuxiang Fu, and Wan He, and Guixiang Liao
January 2010, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology,
Xiaoling Zhong, and Guohua Zeng, and Lixiang Zhang, and Shuyuan You, and Yuxiang Fu, and Wan He, and Guixiang Liao
June 2024, Cancer medicine,
Xiaoling Zhong, and Guohua Zeng, and Lixiang Zhang, and Shuyuan You, and Yuxiang Fu, and Wan He, and Guixiang Liao
June 2013, Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery,
Copied contents to your clipboard!